Table S2 from Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort

Glencer, Alexa C.; Miller, Phoebe N.; Greenwood, Heather; Maldonado Rodas, Cristian K.; Freimanis, Rita; Basu, Amrita; Mukhtar, Rita A.; Brabham, Case; Kim, Paul; Hwang, E. Shelley; Rosenbluth, Jennifer M.; Hirst, Gillian L.; Campbell, Michael J.; Borowsky, Alexander D.; Esserman, Laura J.

doi:10.1158/2767-9764.22545918.v1

Table S2 from Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort

journal contribution

posted on 2023-04-04, 02:00 authored by Alexa C. Glencer, Phoebe N. Miller, Heather Greenwood, Cristian K. Maldonado Rodas, Rita Freimanis, Amrita Basu, Rita A. Mukhtar, Case Brabham, Paul Kim, E. Shelley Hwang, Jennifer M. Rosenbluth, Gillian L. Hirst, Michael J. Campbell, Alexander D. Borowsky, Laura J. Esserman

Supplementary Table 2

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

A retrospective analysis of 71 patients with DCIS who did not undergo upfront surgery demonstrated that breast MRI features after short-term exposure to endocrine therapy identify those at high (68.2%), intermediate (20.0%), and low risk (8.7%) of IDC. With 7.4 years mean follow-up, 52.1% of patients remain on active surveillance. A period of active surveillance offers the opportunity to risk-stratify DCIS lesions and guide decisions for operative management.